BR112012006986A2 - novos derivados de benzimidazol e seu uso como agonistas de fxr - Google Patents
novos derivados de benzimidazol e seu uso como agonistas de fxrInfo
- Publication number
- BR112012006986A2 BR112012006986A2 BR112012006986A BR112012006986A BR112012006986A2 BR 112012006986 A2 BR112012006986 A2 BR 112012006986A2 BR 112012006986 A BR112012006986 A BR 112012006986A BR 112012006986 A BR112012006986 A BR 112012006986A BR 112012006986 A2 BR112012006986 A2 BR 112012006986A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzimidazole derivatives
- fxr agonists
- new benzimidazole
- new
- fxr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171700 | 2009-09-29 | ||
| PCT/EP2010/064217 WO2011039130A1 (en) | 2009-09-29 | 2010-09-27 | New benzimidazole derivatives and their use as fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012006986A2 true BR112012006986A2 (pt) | 2016-04-12 |
Family
ID=43033176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012006986A BR112012006986A2 (pt) | 2009-09-29 | 2010-09-27 | novos derivados de benzimidazol e seu uso como agonistas de fxr |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8309581B2 (pt) |
| EP (1) | EP2483247A1 (pt) |
| JP (1) | JP5503007B2 (pt) |
| KR (1) | KR101477872B1 (pt) |
| CN (1) | CN102574812B (pt) |
| AU (1) | AU2010303146A1 (pt) |
| BR (1) | BR112012006986A2 (pt) |
| CA (1) | CA2772815A1 (pt) |
| HK (1) | HK1171746A1 (pt) |
| IL (1) | IL218037A0 (pt) |
| IN (1) | IN2012DN01234A (pt) |
| MX (1) | MX2012002479A (pt) |
| WO (1) | WO2011039130A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2923090C (en) | 2013-09-11 | 2018-08-21 | Poxel | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
| CN108072684B (zh) * | 2016-11-11 | 2020-06-16 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
| JP2020508316A (ja) | 2017-02-21 | 2020-03-19 | ジェンフィＧｅｎｆｉｔ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| AU2007263807B2 (en) * | 2006-06-29 | 2011-06-02 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| CN102083799B (zh) * | 2007-08-27 | 2013-10-16 | 霍夫曼-拉罗奇有限公司 | 用作fxr激动剂的苯并咪唑衍生物 |
| EP2222645B1 (en) * | 2007-11-15 | 2013-03-20 | F. Hoffmann-La Roche AG | Benzimidazole derivatives and their use as fxr agonists |
| EP2321282B1 (en) * | 2008-09-11 | 2013-03-27 | F. Hoffmann-La Roche AG | New benzimidazole derivatives |
| ES2444791T3 (es) * | 2008-10-15 | 2014-02-26 | F. Hoffmann-La Roche Ag | Nuevos derivados de benzimidazol |
-
2010
- 2010-09-20 US US12/885,588 patent/US8309581B2/en not_active Expired - Fee Related
- 2010-09-27 MX MX2012002479A patent/MX2012002479A/es active IP Right Grant
- 2010-09-27 IN IN1234DEN2012 patent/IN2012DN01234A/en unknown
- 2010-09-27 EP EP10757215A patent/EP2483247A1/en not_active Withdrawn
- 2010-09-27 CN CN201080043283.8A patent/CN102574812B/zh not_active Expired - Fee Related
- 2010-09-27 JP JP2012531341A patent/JP5503007B2/ja not_active Expired - Fee Related
- 2010-09-27 WO PCT/EP2010/064217 patent/WO2011039130A1/en active Application Filing
- 2010-09-27 CA CA2772815A patent/CA2772815A1/en not_active Abandoned
- 2010-09-27 KR KR1020127010681A patent/KR101477872B1/ko not_active IP Right Cessation
- 2010-09-27 AU AU2010303146A patent/AU2010303146A1/en not_active Abandoned
- 2010-09-27 BR BR112012006986A patent/BR112012006986A2/pt not_active Application Discontinuation
-
2012
- 2012-02-09 IL IL218037A patent/IL218037A0/en unknown
- 2012-12-05 HK HK12112513.9A patent/HK1171746A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102574812B (zh) | 2016-03-30 |
| US8309581B2 (en) | 2012-11-13 |
| IL218037A0 (en) | 2012-04-30 |
| KR20120063536A (ko) | 2012-06-15 |
| CN102574812A (zh) | 2012-07-11 |
| MX2012002479A (es) | 2012-03-26 |
| JP2013505977A (ja) | 2013-02-21 |
| HK1171746A1 (zh) | 2013-04-05 |
| WO2011039130A1 (en) | 2011-04-07 |
| EP2483247A1 (en) | 2012-08-08 |
| US20110077273A1 (en) | 2011-03-31 |
| AU2010303146A1 (en) | 2012-04-19 |
| CA2772815A1 (en) | 2011-04-07 |
| KR101477872B1 (ko) | 2014-12-30 |
| JP5503007B2 (ja) | 2014-05-28 |
| IN2012DN01234A (pt) | 2015-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013016030A2 (pt) | compostos e seu uso como inibidores de bace | |
| BRPI1015145A2 (pt) | derivados de tiazol e seu uso como receptores antagonistas de p2y12 | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| BRPI0813412A2 (pt) | Derivados de benzimidazol | |
| BRPI1014582A2 (pt) | benzimidazois, benzotiazois e benzoxazoles substituidos | |
| BR112013014314A2 (pt) | derivados de 6-amino-2-fenilamino-1h-benzimidazol-5-carboxamida e seu uso como inibidores de prostaglandina e2 sintase-1 microssômicas | |
| BR112012010502A2 (pt) | derivados de benzimidazol-imidazol | |
| BRPI0920448A2 (pt) | compostos spiro-oxindol e seu uso como agentes terapêuticos | |
| BRPI1010533A2 (pt) | tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos | |
| BRPI1011572A2 (pt) | Glico-oligossacarídeos compreendendo ligações glicosídias (alfa1-4) e (alfa1-6), seu uso, e métodos para o seu fornecimento | |
| BR112013011520A2 (pt) | pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2 | |
| BRPI0918128A2 (pt) | derivados de heterozril amida e seu uso como ativadores de glicocinase | |
| BRPI1016120A2 (pt) | derivados de benzoxazol, benzimidazol, oxazolopiridina e imidazopiridina substituídos como moduladores de gama secretase. | |
| BR112012024870A2 (pt) | derivados de 4-aminopirimidina e seus antagonistas do receptor a2a de adenosina | |
| BRPI1013432A2 (pt) | derivado de indolizina e uso do mesmo para propósitos médicos | |
| BRPI0913885A8 (pt) | tiadiazoliloxifenilamidinas e seu uso como fungicidas | |
| CO6930362A2 (es) | Compuesto heterocíclico y su uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BR112012008044A2 (pt) | pteridinas e seu uso como agroquímicos | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
| BRPI0814231A2 (pt) | Derivados de pleuromutilina e seu uso como antimicrobianos | |
| BRPI0808025A2 (pt) | Composto de benzimidazol e uso farmacêutico do mesmo | |
| BR112013004662A2 (pt) | agonistas de receptores de neurotrofina e o uso destes como medicamentos | |
| BR112013033316A2 (pt) | antagonista de trpm8 e seu uso em tratamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |